Treatment of myiasis involves manual removal of larvae and surgical debridement, in conjunction with ivermectin and systemic broad-spectrum antimicrobial drugs to prevent secondary infections (1, 2) . Treatment with ivermectin can kill the larvae (1; references 14,15 in the online Technical Appendix) and result in considerable reduction of larvae in infested wounds. Ivermectin has a broad antiparasitic spectrum that causes immobilization of parasites by inducing tonic paralysis of the parasite's muscles, mainly at the pharyngeal level, resulting in the death of the parasites by suffocation and starvation.
For the patient in this report, the single oral dose (0.2 mg/kg) of ivermectin was an effective treatment for myiasis. However, to control the underlying disease and prevent recurrences, ivermectin should be used with oral antimicrobial drugs and wound care when the wound has a high number of larvae, which are associated with bacterial infections (4, 5 To the Editor: The Centers for Disease Control and Prevention and US Preventive Services Task Force recommend a one-time screening for hepatitis C virus (HCV) infection in adults born during 1945-1965 (birth cohort), a demographic group with a disproportionately high prevalence of HCV infection (1, 2) . However, some experts have warned against routine HCV screening of persons in the birth cohort, stating that this recommendation is based on unproven assumptions about the benefit of screening in reducing HCV-related mortality, given that only a minority of infected persons develop end-stage liver disease (ESLD) (3). To determine the relative effect of the birth cohort on HCV-related ESLD incidence in the United States, we analyzed trends in liver transplantation (LT) waitlist registrations and LT surgeries during 1995-2012. Using data from the United Network for Organ Sharing national registry, we evaluated birth cohort-specific (birth cohort vs. non-birth cohort) and etiology-specific (HCV vs. non-HCV) trends in LT waitlist registrations and LT surgeries performed in the United States during that 18-year period.
The proportion of HCV-infected persons born during 1945-1965 among all persons with LT waitlist registrations in the United States increased from 17.8% in 1995 to 35.2% in 2012 (Table) . The highest proportion of LT waitlist registrations for HCV-related ESLD was for persons in the birth cohort and increased incrementally from 61.2% in 1995 to 90.5% in 2012. The proportion of LT waitlist registrations for HCV-related ESLD among persons younger than the birth cohort was 1.0% in 1995 and 3.6% in 2012; among persons older than the birth cohort, the proportion was 37.8% in 1995 and 5.9% in 2012.
Similarly, among LT recipients, the proportion of HCV-infected persons born during 1945-1965 doubled from 17.4% in 1995 to 35.4% in 2012 (Table) . The proportion of LT surgeries performed for HCV-related ESLD among persons in the birth cohort increased from 60.2% in 1995 to 90.7% in 2012. Among persons younger than the birth cohort, the proportion of LT surgeries performed for HCV-related ESLD was 0.7% in 1995 and 5.0% in 2012; among persons older than the birth cohort, the proportion was 39.1% in 1995 and 4.3% in 2012.
During 1995-2012, the ratio of new LT waitlist registrations to LT surgeries performed for HCV-infected persons in the birth cohort remained unchanged at 1.9:2.0 despite the aging of this birth cohort. Overall trends in HCV-related LT waitlist registrations and LT surgeries stabilized during 2001-2012; the proportion of HCV-infected persons in the birth cohort increased, and the proportion of HCV-infected persons not in the birth cohort decreased.
To exclude the possibility that HCV-related ESLD has always simply affected persons 50-70 years of age, we performed a subanalysis examining the proportion of LT waitlist registrations and LT surgeries for persons 50-70 years of age in each year from 1995 through 2012. During this 18-year period, among persons 50-70 years of age, new HCV-related LT waitlist registrations increased from 43.9% to 93.0%, and LT surgeries performed increased from 47.1% to 86.2%. This finding suggests that persons born during 1945-1965 are a distinct birth cohort that is increasingly affected by HCV-related ESLD.
Although persons born during 1945-1965 make up an estimated 27% of the US population, they account for ≈75% of all HCV infections and 73% of HCV-associated deaths in the United (1). Our findings are consistent with those of an earlier modeling study by Davis et al. (4), which suggested that the age of persons with HCV-related cirrhosis and its complications will continue to increase.
Limitations of our study include inherent limitations of retrospective design and registry data. The designation of HCV infection and birth cohort status is based entirely on data entered into the database, which are not necessarily subject to cross-checking confirmatory measures. However, any errors in data entry that may have occurred are probably nondifferential. Despite these limitations, our analysis demonstrates that >90% of HCV-infected persons registered for LT or undergoing LT surgeries in 2012 were in the birth cohort.
Earlier diagnosis and preemptive cure of HCV infection with highly effective and safe direct-acting antiviral drugs may delay or reduce the need for LT among persons in the birth cohort (5) . Testing and linkage to care for HCVinfected persons, particularly persons in the birth cohort, can be expected to reduce HCV-related illness and death (1, 2) . In response to the approval of higher efficacy antiviral drugs and rapidly rising liver failure-related death among this cohort (6, 7) , the use of HCV-infected donors has increased, resulting in truncated wait times for HCVinfected LT recipients in many regions (8) , whereas HCVuninfected persons are generally waiting considerably longer, often years, for HCV-uninfected donors (9 
